Facial Emotion Recognition in Patients With Euthymic Bipolar Disorder I and II
REF-BIP
1 other identifier
interventional
10
1 country
1
Brief Summary
The facial emotion recognition is a basic social skill for successful social interactions. Several meta-analyses and recent studies found impairments of the perception of facial emotions in patients with euthymic bipolar disorder. Few studies compared recognition of facial emotions impairments during euthymia in patients with bipolar disorder type 1 and 2. These studies included low population samples (N\<60). There were discrepancies in results of these studies. Szanto suggested that facial emotion recognition impairments were correlated with suicidal risk and social isolation. These impairments should be taking into account regarding psycho-social treatments in patients with bipolar disorder. This study aims to evaluate facial emotion recognition in patients with bipolar I and II disorders compared to healthy controls, using the facial emotion recognition test (TREF). The objective of the present study is to compare TREF scores in a group of patients with bipolar 1, a group of patients with bipolar 2 disorder and a group with healthy controls. In addition, the investigators will investigate the relationships between TREF scores and levels of self-esteem and mental well-being.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2020
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2023
CompletedFirst Submitted
Initial submission to the registry
June 20, 2023
CompletedFirst Posted
Study publicly available on registry
June 28, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2023
CompletedNovember 19, 2025
November 1, 2025
3.1 years
June 20, 2023
November 17, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
variation of TREF scores in tree groups of subjects
TREF scores in tree groups of subjects (group of patients with bipolar disorder 1, group of patients with bipolar disorder 2 and group of healthy controls.
16 months
Study Arms (3)
patients with bipolar disorder 1
EXPERIMENTALpatients with bipolar disorder 2
EXPERIMENTALhealthy controls
ACTIVE COMPARATORInterventions
Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
Eligibility Criteria
You may qualify if:
- Patient group :
- Male or female patients, between 18 and 60 years old
- Diagnosis of Bipolar Disorder I or Bipolar Disorder II according to DSM-IV criteria, using the French version of the Mini-International Neuropsychiatric Interview (MINI)
- Strictly euthymic defined by Hamilton Depression Rating Scale (17 items) ≤ 5 and Young Mania Rating Scale ≤ 5 for at least two months.
- Native French speakers
- Affiliated to the French social security system
- Giving their written informed consent
- Control group :
- Male or female control subjects, aged between 18 and 60 years old, assessed using TREF
- Native French speakers
- Giving their written informed consent
You may not qualify if:
- Patient group :
- History of mental retardation assessed by the French version of the National Adult Reading Test
- Neurological illness or any clinical condition that could affect cognitive performance (history of head injury with loss of consciousness lasting more than 5 minutes multiple sclerosis, stroke etc.)
- Electroconvulsive therapy within the last 6 months
- Alcohol and Drug dependence (except tobacco and caffeine) according to DSM-IV criteria using the French version of the Mini-International Neuropsychiatric Interview (MINI).
- Learning disability or difficulty with fluent use of the French language
- Patient with mandatory care
- Long-Term use of non-psychotropic medication with psychotropic effects (opiates, Baclofen)
- Control group :
- History of mental retardation estimated by the French version of the National Adult Reading Test
- Neurological illness or any clinical condition that could affect cognitive performance (history of head injury with loss of consciousness lasting more than 5 minutes multiple sclerosis, stroke etc.)
- Current Mood disorder/ Lifetime Psychotic Disorder according to DSM-IV criteria using the French version of the Mini-International Neuropsychiatric Interview (MINI)
- Neither history of psychotic or affective disorders in a first-degree family member
- Alcohol and Drug dependence (except tobacco and caffeine) according to DSM-IV criteria using the French version of the Mini-International Neuropsychiatric Interview (MINI)
- Learning disability or difficulty with fluent use of the French language
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU Amiens
Amiens, 80480, France
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 20, 2023
First Posted
June 28, 2023
Study Start
April 1, 2020
Primary Completion
May 1, 2023
Study Completion
July 1, 2023
Last Updated
November 19, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share